Cellectis Stock Forecast, Price & News

5 Wall Street equities research analysts have issued "buy," "hold," and "sell" ratings for Cellectis in the last twelve months. There are currently 1 hold rating and 4 buy ratings for the stock. The consensus among Wall Street equities research analysts is that investors should "buy" Cellectis stock.
View analyst ratings for Cellectis or view top-rated stocks.

Wall Street analysts have given Cellectis a "Buy" rating, but there may be better buying opportunities in the stock market. Some of MarketBeat's past winning trading ideas have resulted in 5-15% weekly gains. MarketBeat just released five new stock ideas, but Cellectis wasn't one of them. MarketBeat thinks these five companies may be even better buys.
View MarketBeat's top stock picks here.

Cellectis saw a drop in short interest in the month of June. As of June 15th, there was short interest totaling 1,190,000 shares, a drop of 21.7% from the May 31st total of 1,520,000 shares. Based on an average daily trading volume, of 267,100 shares, the short-interest ratio is presently 4.5 days. Currently, 2.6% of the company's shares are sold short.
View Cellectis' Short Interest.

Cellectis is scheduled to release its next quarterly earnings announcement on Thursday, August 5th 2021.
View our earnings forecast for Cellectis.

Cellectis will be holding an earnings conference call on Friday, August 6th at 8:00 AM Eastern. Interested parties can register for or listen to the call using this link or dial in at 877-660-6853 with passcode "13721394".

Cellectis S.A. (NASDAQ:CLLS) announced its quarterly earnings data on Thursday, May, 6th. The biotechnology company reported ($0.28) earnings per share for the quarter, topping the consensus estimate of ($0.82) by $0.54. The biotechnology company earned $27.97 million during the quarter, compared to analyst estimates of $8.14 million. Cellectis had a negative net margin of 200.21% and a negative trailing twelve-month return on equity of 36.24%.
View Cellectis' earnings history.

Cellectis' stock was trading at $11.43 on March 11th, 2020 when Coronavirus (COVID-19) reached pandemic status according to the World Health Organization. Since then, CLLS shares have increased by 18.9% and is now trading at $13.59.
View which stocks have been most impacted by COVID-19.

5 Wall Street analysts have issued twelve-month target prices for Cellectis' shares. Their forecasts range from $32.00 to $39.00. On average, they anticipate Cellectis' share price to reach $34.67 in the next twelve months. This suggests a possible upside of 155.1% from the stock's current price.
View analysts' price targets for Cellectis or view top-rated stocks among Wall Street analysts.

4 employees have rated Cellectis CEO André Choulika on Glassdoor.com. André Choulika has an approval rating of 100% among Cellectis' employees. This puts André Choulika in the top 10% of approval ratings compared to other CEOs of publicly-traded companies.

Some companies that are related to Cellectis include Translate Bio (TBIO), Revolution Medicines (RVMD), Alector (ALEC), Rubius Therapeutics (RUBY), C4 Therapeutics (CCCC), Instil Bio (TIL), Cortexyme (CRTX), bluebird bio (BLUE), Century Therapeutics (IPSC), Replimune Group (REPL), Valneva (VALN), Immunocore (IMCR), Sangamo Therapeutics (SGMO), BioAtla (BCAB) and REGENXBIO (RGNX).
View all of CLLS's competitors.

Based on aggregate information from My MarketBeat watchlists, some companies that other Cellectis investors own include Gilead Sciences (gild), Calyxt (CLXT), NVIDIA (NVDA), AbbVie (ABBV), Micron Technology (MU), Advanced Micro Devices (AMD), CRISPR Therapeutics (CRSP), Editas Medicine (EDIT), Intel (INTC) and Sorrento Therapeutics (SRNE).

(CLLS) raised $129 million in an IPO on Wednesday, March 25th 2015. The company issued 3,500,000 shares at a price of $36.83 per share. BofA Merrill Lynch, Jefferies and Piper Jaffray served as the underwriters for the IPO and Oppenheimer was co-manager.

Cellectis trades on the NASDAQ under the ticker symbol "CLLS."

Cellectis' stock is owned by a number of institutional and retail investors. Top institutional investors include Baillie Gifford & Co. (2.27%), Sumitomo Mitsui Trust Holdings Inc. (1.75%) and Exchange Traded Concepts LLC (0.49%).

CLLS stock was sold by a variety of institutional investors in the last quarter, including Sumitomo Mitsui Trust Holdings Inc..

CLLS stock was bought by a variety of institutional investors in the last quarter, including Baillie Gifford & Co., and Exchange Traded Concepts LLC.

Shares of CLLS can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
Compare Top Brokerages Here.

One share of CLLS stock can currently be purchased for approximately $13.59.

Cellectis has a market capitalization of $617.81 million and generates $82.46 million in revenue each year. The biotechnology company earns $-81,070,000.00 in net income (profit) each year or ($1.91) on an earnings per share basis.

Cellectis employs 272 workers across the globe.

The official website for Cellectis is www.cellectis.com.

Cellectis is headquartered at 8 RUE DE LA CROIX JARRY, PARIS I0, 75013.

Cellectis' mailing address is 8 RUE DE LA CROIX JARRY, PARIS I0, 75013. The biotechnology company can be reached via phone at 33-1-81-69-16-00 or via email at [email protected]